Loading stock data…
$3.67-0.06 (-1.61%)
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.
Prime Medicine, Inc. in the Healthcare sector is trading at $3.67 with a market capitalization of $629M. Wall Street consensus targets $7.11 (11 analysts), implying a +93.8% move over the next 12 months. The stock is currently 29% below its 52-week high of $5.20, remaining 5.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.15M↑ | $856,000↑ | $838,000↓ | $1.23M↑ | $1.11M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$43.28M↑ | -$50.65M↓ | -$48.61M↑ | -$53.97M↓ | -$53.38M |
| Net Income | -$42.11M↑ | -$49.12M↓ | -$46.08M↑ | -$50.58M↑ | -$52.59M |
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulom...